Showing results (211-220 of 333) with videos related to

Sort By:
Pageof 34
International Journal of Clinical Oncology|June 12, 2021
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinibRyoji Kato, Hidetoshi Hayashi, Kazuko Sakai, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2013
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lungHidemi Kiyota, Isamu Okamoto, Masayuki Takeda, et al.
International Cancer Conference Journal|March 31, 2025
Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitorsAkiho Nagayama, Chiho Miyagawa, Yoko Kashima, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2025
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancerTakashi Kurosaki, Hiroaki Kanemura, Tomoyuki Otani, et al.
Molecular and Clinical Oncology|March 21, 2014
Overexpression of heparan sulfate 6-<i>O</i>-sulfotransferase-2 in colorectal cancerShigeru Hatabe, Hideharu Kimura, Tokuzo Arao, et al.
JTO Clinical and Research Reports|May 2, 2022
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer SocietyYuichi Ozawa, Nobuyuki Yamamoto, Kouji Yamamoto, et al.
International Journal of Hematology|January 26, 2022
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trialYoshinori Imamura, Kazunori Otsui, Kenta Mori, et al.
Clinical Lung Cancer|June 18, 2017
A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L StudyHidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, et al.
Breast Cancer (Tokyo, Japan)|November 30, 2011
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610BHidetoshi Hayashi, Junji Tsurutani, Taro Satoh, et al.
Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.
Pageof 34